1. Tigermed (03347.HK): The company plans to sell its control over its subsidiary, Fangda Holdings, and divest Fangda Holdings' overseas laboratory business.
2. Datang Gold (08299.HK): The company expects total profit attributable to owners of the company to be approximately HK$208 million for the six months ended September 30, 2026.
3. Guangzhou Baiyunshan Pharmaceutical (00874.HK): Guangzhou Pharmaceutical plans to introduce strategic investors and conduct a private placement of shares, with an expected fundraising amount not exceeding RMB 6 billion.
4. Agile Group (03383.HK): The total pre-sale amount for the first ten months of 2026 was approximately RMB 5.18 billion, corresponding to a construction area of approximately 587,000 square meters, with an average price of RMB 8,825 per square meter.
5. Q Technology (01478.HK): In October 2026, the group's mobile phone sales volume was 38.845 million units, a decrease of 22.6% month-on-month and 37.7% year-on-year; among which, camera module sales volume was 23.904 million units, a decrease of 34.2% month-on-month and 45.7% year-on-year.
6. COSCO Shipping Energy Transportation (01138.HK) announced that its wholly-owned subsidiary, Hainan Haineng, signed a contract with Dalian Shipbuilding Industry Co., Ltd. to build four VLCC crude oil tankers, with a total contract price of RMB 3.793 billion and a total investment of approximately RMB 3.829 billion.
7. Rongchang Biotechnology (09995.HK) announced that it signed a "Licensing Agreement" with Yantai Rongchang Pharmaceutical, obtaining a global exclusive license for pan-RAS(ON) small molecule inhibitors. The company will pay an initial payment of RMB 50 million, with maximum milestone payments of RMB 4.87 billion, and royalties based on 3%-7% of annual net sales.
8. Longyuan Power (00916.HK): In the first 10 months of 2026, the company's cumulative power generation reached 64.128 million MWh, a year-on-year increase of 3.18%; in October, on a consolidated basis, the company's power generation reached 6.8742 million MWh, a year-on-year increase of 22.64%.
9. WuXi AppTec (02359.HK) announced: On November 9, 2026, we learned that the U.S. Department of Defense decided to remove WuXi AppTec from the CMC list under Item 1260H.
10. Ribobio-B (06938.HK) submitted a Phase I clinical trial application for its dual-target drug SR122 injection for the treatment of mixed dyslipidemia and severe hypertriglyceridemia.
